Product
efgartigimod
Aliases
ARGX-113
3 clinical trials
2 indications
Indication
Myasthenia GravisIndication
Immune ThrombocytopeniaClinical trial
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod AlfaStatus: Not yet recruiting, Estimated PCD: 2034-06-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune ThrombocytopeniaStatus: Completed, Estimated PCD: 2022-02-03
Clinical trial
A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia.Status: Active (not recruiting), Estimated PCD: 2025-07-01